301 related articles for article (PubMed ID: 35878733)
1. Safety and immunogenicity of inactivated COVID-19 vaccination in adult rheumatic patients in South China: a prospective study.
Zeng H; Liu H; Liu Z; Zhou X; Lu X; Yan Z; Zhou Y; Dai L; Chen Y; Yang T; Yin Z; Ye Z
Hum Vaccin Immunother; 2022 Nov; 18(5):2090176. PubMed ID: 35878733
[TBL] [Abstract][Full Text] [Related]
2. Safety, immunogenicity, and protective effective of inhaled COVID-19 vaccines: A systematic review and meta-analysis.
Song G; Li R; Cheng MQ
J Med Virol; 2024 Apr; 96(4):e29625. PubMed ID: 38650361
[TBL] [Abstract][Full Text] [Related]
3. Safety and immunogenicity of COVID-19 vaccination in patients with non-alcoholic fatty liver disease (CHESS2101): A multicenter study.
Wang J; Hou Z; Liu J; Gu Y; Wu Y; Chen Z; Ji J; Diao S; Qiu Y; Zou S; Zhang A; Zhang N; Wang F; Li X; Wang Y; Liu X; Lv C; Chen S; Liu D; Ji X; Liu C; Ren T; Sun J; Zhao Z; Wu F; Li F; Wang R; Yan Y; Zhang S; Ge G; Shao J; Yang S; Liu C; Huang Y; Xu D; Li X; Ai J; He Q; Zheng MH; Zhang L; Xie Q; Rockey DC; Fallowfield JA; Zhang W; Qi X
J Hepatol; 2021 Aug; 75(2):439-441. PubMed ID: 33905793
[TBL] [Abstract][Full Text] [Related]
4. Safety and immunogenicity of inactivated COVID-19 vaccine in patients with metabolic syndrome: A cross-sectional observational study.
Guo Q; Yang L; Peng R; Gao T; Chu X; Jiang D; Ke D; Ren H
Front Public Health; 2022; 10():1067342. PubMed ID: 36620297
[TBL] [Abstract][Full Text] [Related]
5. A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial.
Akova M; Unal S
Trials; 2021 Apr; 22(1):276. PubMed ID: 33849629
[TBL] [Abstract][Full Text] [Related]
6. Safety and immunogenicity of inactivated COVID-19 vaccine in health care workers.
Benjamanukul S; Traiyan S; Yorsaeng R; Vichaiwattana P; Sudhinaraset N; Wanlapakorn N; Poovorawan Y
J Med Virol; 2022 Apr; 94(4):1442-1449. PubMed ID: 34783049
[TBL] [Abstract][Full Text] [Related]
7. Safety and immunogenicity of the SARS-CoV-2 ARCoV mRNA vaccine in Chinese adults: a randomised, double-blind, placebo-controlled, phase 1 trial.
Chen GL; Li XF; Dai XH; Li N; Cheng ML; Huang Z; Shen J; Ge YH; Shen ZW; Deng YQ; Yang SY; Zhao H; Zhang NN; Zhang YF; Wei L; Wu KQ; Zhu MF; Peng CG; Jiang Q; Cao SC; Li YH; Zhao DH; Wu XH; Ni L; Shen HH; Dong C; Ying B; Sheng GP; Qin CF; Gao HN; Li LJ
Lancet Microbe; 2022 Mar; 3(3):e193-e202. PubMed ID: 35098177
[TBL] [Abstract][Full Text] [Related]
8. Safety, immunogenicity and protective effect of sequential vaccination with inactivated and recombinant protein COVID-19 vaccine in the elderly: a prospective longitudinal study.
Liu HH; Xie Y; Yang BP; Wen HY; Yang PH; Lu JE; Liu Y; Chen X; Qu MM; Zhang Y; Hong WG; Li YG; Fu J; Wang FS
Signal Transduct Target Ther; 2024 May; 9(1):129. PubMed ID: 38740763
[TBL] [Abstract][Full Text] [Related]
9. Safety and immunogenicity of heterologous boost immunization with an adenovirus type-5-vectored and protein-subunit-based COVID-19 vaccine (Convidecia/ZF2001): A randomized, observer-blinded, placebo-controlled trial.
Jin P; Guo X; Chen W; Ma S; Pan H; Dai L; Du P; Wang L; Jin L; Chen Y; Shi F; Liu J; Xu X; Zhang Y; Gao GF; Chen C; Feng J; Li J; Zhu F
PLoS Med; 2022 May; 19(5):e1003953. PubMed ID: 35617368
[TBL] [Abstract][Full Text] [Related]
10. Effect of an Inactivated Vaccine Against SARS-CoV-2 on Safety and Immunogenicity Outcomes: Interim Analysis of 2 Randomized Clinical Trials.
Xia S; Duan K; Zhang Y; Zhao D; Zhang H; Xie Z; Li X; Peng C; Zhang Y; Zhang W; Yang Y; Chen W; Gao X; You W; Wang X; Wang Z; Shi Z; Wang Y; Yang X; Zhang L; Huang L; Wang Q; Lu J; Yang Y; Guo J; Zhou W; Wan X; Wu C; Wang W; Huang S; Du J; Meng Z; Pan A; Yuan Z; Shen S; Guo W; Yang X
JAMA; 2020 Sep; 324(10):951-960. PubMed ID: 32789505
[TBL] [Abstract][Full Text] [Related]
11. Safety and immunogenicity of SARS-CoV-2 vaccines in Chinese patients with cirrhosis: a prospective multicenter study.
Wang J; Zhang Q; Ai J; Liu D; Liu C; Xiang H; Gu Y; Guo Y; Lv J; Huang Y; Liu Y; Xu D; Chen S; Li J; Li Q; Liang J; Bian L; Zhang Z; Guo X; Feng Y; Liu L; Zhang X; Zhang Y; Xie F; Jiang S; Qin W; Wang X; Rao W; Zhang Q; Tian Q; Zhu Y; Cong Q; Xu J; Hou Z; Zhang N; Zhang A; Zu H; Wang Y; Yan Z; Du X; Hou A; Yan Y; Qiu Y; Wu H; Hu S; Deng Y; Ji J; Yang J; Huang J; Zhao Z; Zou S; Ji H; Ge G; Zhong L; He S; Yan X; Yangzhen BB; Qu C; Zhang L; Yang S; Gao X; Lv M; Zhu Q; Xu X; Zeng QL; Qi X; Zhang W
Hepatol Int; 2022 Jun; 16(3):691-701. PubMed ID: 35403977
[TBL] [Abstract][Full Text] [Related]
12. Robust neutralizing antibody response to SARS-CoV-2 mRNA vaccination in adolescents and young adults with childhood-onset rheumatic diseases.
Yeo JG; Chia WN; Teh KL; Book YX; Hoh SF; Gao X; Das L; Zhang J; Sutamam N; Lim AJM; Poh SL; Tay SH; Nay Yaung K; Ong XM; Hazirah SN; Chua CJH; Leong JY; Wang LF; Albani S; Arkachaisri T
Rheumatology (Oxford); 2022 Nov; 61(11):4472-4481. PubMed ID: 35199166
[TBL] [Abstract][Full Text] [Related]
13. The safety and immunogenicity of inactivated COVID-19 vaccine in old pulmonary tuberculosis patients.
Yang L; Xiang F; Wang D; Guo Q; Deng B; Jiang D; Ren H
Eur J Clin Microbiol Infect Dis; 2023 Apr; 42(4):503-512. PubMed ID: 36849838
[TBL] [Abstract][Full Text] [Related]
14. Characterization of SARS-CoV-2-Specific Humoral and Cellular Immune Responses Induced by Inactivated COVID-19 Vaccines in a Real-World Setting.
Li Z; Xiang T; Liang B; Deng H; Wang H; Feng X; Quan X; Wang X; Li S; Lu S; Yang X; Wang B; Zelinskyy G; Trilling M; Sutter K; Lu M; Dittmer U; Yang D; Zheng X; Liu J
Front Immunol; 2021; 12():802858. PubMed ID: 35003131
[TBL] [Abstract][Full Text] [Related]
15. Dynamics of T follicular helper cells in patients with rheumatic diseases and subsequent antibody responses in a three-dose immunization regimen of CoronaVac.
Zhou X; Wang Y; Huang B; Feng R; Zhou X; Li C; Zhang X; Shao M; Gan Y; Jin Y; An Y; Xiao X; Wang S; Liu Q; Cheng G; Zhu F; Zhang K; Wang N; Xing X; Li R; Li Y; Liu Y; Lu D; Sun X; Li Z; Liu Y; He J
Immunology; 2023 Jan; 168(1):184-197. PubMed ID: 36057099
[TBL] [Abstract][Full Text] [Related]
16. Systemic autoimmune myopathies: a prospective phase 4 controlled trial of an inactivated virus vaccine against SARS-CoV-2.
Shinjo SK; de Souza FHC; Borges IBP; Dos Santos AM; Miossi R; Misse RG; Medeiros-Ribeiro AC; Saad CGS; Yuki EFN; Pasoto SG; Kupa LVK; Ceneviva C; Seraphim JC; Pedrosa TN; Vendramini MBG; Silva CA; Aikawa NE; Bonfá E
Rheumatology (Oxford); 2022 Aug; 61(8):3351-3361. PubMed ID: 34664616
[TBL] [Abstract][Full Text] [Related]
17. Safety and immunogenicity of COVID-19 vaccination in patients with hepatocellular carcinoma (CHESS-NMCID 2101): A multicenter prospective study.
Qi X; Wang J; Zhang Q; Ai J; Liu C; Li Q; Gu Y; Lv J; Huang Y; Liu Y; Xu D; Chen S; Liu D; Li J; Xiang H; Liang J; Bian L; Zhang Z; Liu L; Zhang X; Qin W; Wang X; Hou Z; Zhang N; Zhang A; Zu H; Wang Y; Yan Z; Du X; Hou A; Ji J; Yang J; Huang J; Zhao Z; Zou S; Ji H; Ge G; Zeng QL; Zhang W
J Med Virol; 2022 Nov; 94(11):5553-5559. PubMed ID: 35811309
[TBL] [Abstract][Full Text] [Related]
18. Safety, immunogenicity, and immune persistence of two inactivated COVID-19 vaccines replacement vaccination in China: An observational cohort study.
Wang X; Deng Y; Zhao L; Wang L; Fu Z; Tang L; Ye F; Liu Q; Wang W; Wang S; Hu B; Guan X; Han Z; Tong Y; Rodewald LE; Yin Z; Tan W; Wang F; Huang B
Vaccine; 2022 Sep; 40(39):5701-5708. PubMed ID: 36031501
[TBL] [Abstract][Full Text] [Related]
19. Immunogenicity, efficacy, and safety of CoronaVac and Pfizer/BioNTech mRNA vaccines in patients with psoriasis receiving systemic therapies: A prospective cohort study.
Ergun T; Hosgoren Tekin S; Apti Sengun O; Akin Cakici O; Seckin D; Adiay C; Enul H; Yilmaz S; Ay P; Haklar G; Sili U
Vaccine; 2023 Jun; 41(29):4287-4294. PubMed ID: 37277251
[TBL] [Abstract][Full Text] [Related]
20. Safety and Immunogenicity of SARS-CoV-2 Vaccines in Patients With Chronic Liver Diseases (CHESS-NMCID 2101): A Multicenter Study.
Ai J; Wang J; Liu D; Xiang H; Guo Y; Lv J; Zhang Q; Li J; Zhang X; Li Q; Liang J; Guo X; Feng Y; Liu L; Zhang X; Qin W; Wang X; Rao W; Zhang Q; Tian Q; Zhang Y; Xie F; Jiang S; Yan Y; Qiu Y; Wu H; Hou Z; Zhang N; Zhang A; Ji J; Yang J; Huang J; Zhao Z; Gu Y; Bian L; Zhang Z; Zou S; Ji H; Ge G; Du X; Hou A; Zhu Y; Cong Q; Xu J; Zu H; Wang Y; Yan Z; Yan X; BianBa Y; Ci Q; Zhang L; Yang S; Gao X; Zhong L; He S; Liu C; Huang Y; Liu Y; Xu D; Zhu Q; Xu X; Lv M; Zhang W; Qi X
Clin Gastroenterol Hepatol; 2022 Jul; 20(7):1516-1524.e2. PubMed ID: 34942370
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
